Yamamoto Noboru, Sato Kaoru, Hoshina Takayuki, Kojiro Masumi, Kusuhara Koichi
a Department of Pediatrics , Kitakyushu General Hospital , Kitakyushu , Japan.
b Department of Pediatrics , School of Medicine, University of Occupational and Environmental Health , Kitakyushu , Japan.
Mod Rheumatol. 2015;25(6):898-902. doi: 10.3109/14397595.2015.1038430. Epub 2015 May 27.
The aim of this study is to investigate whether ferritin can be a useful marker for the prediction of the patients with Kawasaki disease (KD) refractory to initial intravenous immunoglobulin (IVIG) therapy.
This retrospective study enrolled 85 patients with KD hospitalized at Kitakyushu General Hospital during 2010-2014. These patients were divided into IVIG responders (n = 57) and non-responders (n = 28). Serum ferritin levels and the scoring systems for the prediction of non-responsiveness to initial IVIG therapy were compared between these two groups.
Serum ferritin level was significantly elevated in non-responders (p = 0.010). The area under the receiver-operating characteristics curve was 0.674, and the sensitivity and specificity in more than 165 ng/ml of serum ferritin level were 70.4% and 63.2%, respectively. In two of the three prediction scoring systems, non-responders also showed significantly higher scores than responders, but many non-responders had low scores of these scoring systems. More than half of the patients with a low score of these scoring systems had high serum ferritin level (≥ 165 ng/ml).
Serum ferritin level might be a useful marker for the prediction of non-responsiveness to initial IVIG therapy and could be an important complementary marker to the prediction scoring systems.
本研究旨在探讨铁蛋白是否可作为预测初次静脉注射免疫球蛋白(IVIG)治疗无效的川崎病(KD)患者的有用标志物。
这项回顾性研究纳入了2010年至2014年期间在北九州综合医院住院的85例KD患者。这些患者被分为IVIG反应者(n = 57)和无反应者(n = 28)。比较了这两组患者的血清铁蛋白水平以及预测初次IVIG治疗无反应性的评分系统。
无反应者的血清铁蛋白水平显著升高(p = 0.010)。受试者工作特征曲线下面积为0.674,血清铁蛋白水平超过165 ng/ml时的敏感性和特异性分别为70.4%和63.2%。在三个预测评分系统中的两个中,无反应者的得分也显著高于反应者,但许多无反应者在这些评分系统中的得分较低。这些评分系统得分低的患者中,超过一半的患者血清铁蛋白水平较高(≥165 ng/ml)。
血清铁蛋白水平可能是预测初次IVIG治疗无反应性的有用标志物,并且可能是预测评分系统的重要补充标志物。